Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
Back

Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

London Southampton Oxford Manchester Glasgow Liverpool Middlesex Cambridge Sheffield Newcastle

Medical Conditions

Melanoma

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma.

This research study is investigating using a new blood test to decide when to give a drug called tebentafusp. Tebentafusp has been used in clinical trials in patients with advanced cutaneous and uveal melanoma. This study is designed to determine if tebentafusp can help patients with cutaneous or uveal melanoma live longer.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jul 2022 Dec 2026

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.

Intervention Arm Group : Cutaneous melanoma with molecular relapsed disease;Uveal melanoma with molecular relapsed disease;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • University College London Hospital
    London
  • University Hospital Southampton NHS Foundation Trust
    Southampton
  • Churchill Hospital, Oxford University Hospitals NHS Trust
    Oxford
    OX3 7LE
  • The Christie Hospital
    Manchester
  • The Beatson West of Scotland Cancer Centre
    Glasgow
  • The Clatterbridge Cancer Centre
    Liverpool
  • Mount Vernon Cancer Centre
    Middlesex
  • Cambridge University Hospitals NHS Foundation Trust (Screening only)
    Cambridge
  • Sheffield Teaching Hospitals NHS Foundation Trust (Screening only)
    Sheffield
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
    Newcastle


The study is sponsored by University of Oxford and is in collaboration with Immunocore Ltd.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05315258
Last updated 14 July 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top